1. Home
  2. ROK vs ARGX Comparison

ROK vs ARGX Comparison

Compare ROK & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rockwell Automation Inc.

ROK

Rockwell Automation Inc.

HOLD

Current Price

$423.81

Market Cap

47.3B

Sector

Industrials

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$843.84

Market Cap

50.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROK
ARGX
Founded
1903
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.3B
50.4B
IPO Year
1987
2017

Fundamental Metrics

Financial Performance
Metric
ROK
ARGX
Price
$423.81
$843.84
Analyst Decision
Buy
Strong Buy
Analyst Count
14
19
Target Price
$415.77
$979.22
AVG Volume (30 Days)
659.0K
402.2K
Earning Date
02-05-2026
02-26-2026
Dividend Yield
1.33%
N/A
EPS Growth
N/A
N/A
EPS
7.67
23.27
Revenue
$8,342,000,000.00
$3,683,281,000.00
Revenue This Year
$7.12
$91.44
Revenue Next Year
$5.82
$36.90
P/E Ratio
$54.09
$33.83
Revenue Growth
0.94
92.98
52 Week Low
$215.00
$510.06
52 Week High
$429.58
$934.62

Technical Indicators

Market Signals
Indicator
ROK
ARGX
Relative Strength Index (RSI) 59.85 53.22
Support Level $413.71 $810.52
Resistance Level $429.58 $881.89
Average True Range (ATR) 8.14 20.92
MACD 0.02 7.13
Stochastic Oscillator 83.34 64.93

Price Performance

Historical Comparison
ROK
ARGX

About ROK Rockwell Automation Inc.

With roots tracing back to the early 1900s, Rockwell Automation is the successor to Rockwell International, which spun off its avionics segment in 2001. It is a pure-play industrial automation company that operates through three segments. Its largest segment by revenue, intelligent devices, sells factory floor-level devices such as motors, drives, sensors, relays, and actuators. Its software and control segment sells visualization, simulation, and human-machine interface software and control products such as programmable controllers, computers, and operator terminals. Its smallest segment, lifecycle services, offers digital consulting, engineered-to-order services, and other outsourced services such as remote monitoring, cybersecurity, and asset and plant maintenance and optimization.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: